Document is current
Any future updates will be listed below
-
Authors
Peradze, Natia
Farr, Olivia M.
Perakakis, Nikolaos
Lázaro, Iolanda
Sala-Vila, Aleix
Mantzoros, Christos S. https://orcid.org/0000-0003-3755-8158
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02944500 at ClinicalTrials.govDocuments that mention this clinical trial
Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
https://doi.org/10.1186/s12933-019-0945-7
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (389891681)
Instituto de Salud Carlos III (CP II 17/00029)
Novo Nordisk (Investigator-initiated study Grant)
- License Information
-
More Information
Article History
Received: 4 September 2019
Accepted: 11 October 2019
First Online: 31 October 2019
Ethics approval and consent to participate
: The study was performed in Beth Israel Deaconess Medical Center (BIDMC) MA, USA, with prior approval of Institutional Review Board (IRB) from 2016 until 2018. The study followed the Consolidated Standards of Reporting (CONSORT) guidelines and the International Conference on Harmonization for Good Clinical Practice [] (Additional file : Consort Flow Diagram).IRB of BIDMC reviewed and approved advertisement and fliers prior to use, as well as the informed consent forms. Personal information was collected according to the standardized ethics rules. After explaining the purpose and the procedures of the study and risks and benefits, a written informed consent was obtained for participation in this randomized, placebo-controlled, cross-over, double-blind study.
: All authors have seen and read the material to be published and give the consent for publication to the Cardiovascular Diabetology.
: CSM has received consulting fees, an investigator-initiated study grant from Novo Nordisk and research support through his institution, BIDMC, for investigator-initiated research. CSM is an advisor of Ansh Labs LLC. Other authors have no competing interests to declare.
